Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges
Pharmaceutical Medicine · 2024
DOI: 10.1007/s40290-024-00518-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Medicine, 2024. Verfasst von Shubhadeep D Sinha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Development and Medical Affairs, Hetero Labs Limited, Hetero Corporate, 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad, T…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Development and Medical Affairs, Hetero Labs Limited, Hetero Corporate, 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad, Telangana, 500018, India. SD.Sinha@hetero.com.
- Department of Clinical Development and Medical Affairs, Hetero Labs Limited, Hetero Corporate, 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad, Telangana, 500018, India.
ORCID-Profile: Shubhadeep D Sinha, Sreenivasa Chary Sriramadasu
Zitieren
APA
Sinha, S. D., Chary Sriramadasu, S., Raphael, R., & Roy, S. (2024). Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges. Pharmaceutical Medicine. https://doi.org/10.1007/s40290-024-00518-x
Vancouver
Sinha SD, Chary Sriramadasu S, Raphael R, Roy S. Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges. Pharmaceutical Medicine. 2024. doi:10.1007/s40290-024-00518-x
BibTeX
@article{Sinha2024,
author = {Sinha, Shubhadeep D and Chary Sriramadasu, Sreenivasa and Raphael, Ruby and Roy, Sudeshna},
title = {Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges},
journal = {Pharmaceutical Medicine},
year = {2024},
doi = {10.1007/s40290-024-00518-x}
}
EUVIMED